Steep Hill Inc (STPH) AI Stock Analysis

• Market Cap: C$970.72K
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): 2.9
• Beta (1Y): -0.65
• Revenue Growth: N/A
• EPS Growth: -57.35%
• Country: CA
• Employees: 6
• Sector: Healthcare
• Sector Strength: 48
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.02
• Shares Outstanding: 16,178,654
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.01
• Price to Book (P/B): 0.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Steep Hill Inc's overall stock score reflects significant concerns about financial performance due to a lack of revenue and negative cash flows, despite a strong balance sheet. However, positive technical indicators and the strategic acquisition of Lir Life Sciences provide promising growth prospects, boosting investor sentiment and potential market positioning.

Steep Hill Inc Business Overview & Revenue Model

Company Description

Steep Hill Inc (STPH) is a leading analytical testing and research company specializing in cannabis science. The company operates within the biotechnology and healthcare sectors, providing comprehensive laboratory services that include quality assurance, potency testing, and contamination analysis for cannabis and hemp products. Steep Hill Inc is recognized for its state-of-the-art facilities and advanced testing methodologies, serving cultivators, manufacturers, and regulatory bodies to ensure compliance and safety in the cannabis industry.

How the Company Makes Money

Steep Hill Inc generates revenue primarily through its laboratory testing services. Key revenue streams include fees charged for cannabis potency testing, which measures the levels of THC and CBD present in products, and safety screening for contaminants such as pesticides, heavy metals, and microbial impurities. The company also earns from providing consulting services to cannabis businesses, aiding them in meeting regulatory standards and improving product quality. Steep Hill has established significant partnerships with cannabis producers and government agencies to support industry standards and compliance, enhancing its revenue potential through long-term contracts and collaborative projects.

Steep Hill Inc Financial Statement Overview

Summary

Steep Hill Inc's financial health presents concerns, primarily due to the lack of revenue and negative operating cash flows. Although the balance sheet shows a strong equity position, the company's long-term sustainability is at risk without revenue generation. Continued focus on operational efficiency and revenue growth is critical for future stability.

Income Statement

Steep Hill Inc has exhibited a challenging financial performance, with no revenue reported for the latest TTM period, and a history of negative EBIT and EBITDA margins, indicating persistent operational inefficiencies. Although there was a positive net income in the latest TTM, this is likely due to non-operational factors, given the absence of revenue.

Balance Sheet

The company's balance sheet shows a strong equity position with no debt reported in the latest TTM, indicating financial stability and low leverage risk. However, the equity ratio has fluctuated, reflecting changes in asset composition. The return on equity is positive due to net income, but sustainability remains questionable without revenue.

Cash Flow

Operating cash flow has been negative in the latest TTM period, reflecting cash usage in operations without corresponding revenue inflows. The free cash flow growth rate has been negative, indicating a deteriorating cash position. The company's reliance on financing activities suggests potential liquidity challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	1.18M	938.57K	0.00
	Gross Profit
-15.37K	-16.64K	675.48K	938.57K	-118.78K
	EBIT
-218.49K	-482.64K	-2.07M	-3.32M	-2.07M
	EBITDA
-188.23K	-444.66K	-3.73M	-3.97M	-1.95M
	Net Income Common Stockholders
337.71K	793.30K	-4.31M	-4.53M	-2.08M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.21M	2.61M	1.91M	2.58M	438.63K
	Total Assets
2.28M	2.76M	3.02M	7.43M	1.70M
	Total Debt
0.00	18.55K	79.97K	718.20K	442.48K
	Net Debt
-213.93K	-594.86K	-1.83M	-1.86M	3.85K
	Total Liabilities
258.56K	1.11M	2.17M	1.73M	551.85K
	Stockholders Equity
2.02M	1.65M	842.34K	5.77M	1.20M
Cash Flow		Free Cash Flow
-381.46K	742.34K	-1.82M	-1.57M	-1.56M
	Operating Cash Flow
-381.46K	742.34K	-1.82M	-1.57M	-1.25M
	Investing Cash Flow
0.00	-2.00M	1.48M	-336.96K	-280.03K
	Financing Cash Flow
-19.06K	-53.22K	-253.84K	4.04M	402.02K

Steep Hill Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:STPH, the sentiment is Positive. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 62.91 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:STPH.

Steep Hill Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STPH	57 Neutral	C$970.72K	2.87	-11.62%	―	―	-57.35%
OGI	57 Neutral	$227.26M	17.29	4.76%	―	26.93%	―
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%
ACB	50 Neutral	$387.48M	30.37	4.78%	―	16.39%	-98.10%

Steep Hill Inc Corporate Events

Steep Hill Inc. to Acquire Lir Life Sciences in Strategic Reverse Takeover

Steep Hill Inc. has signed an agreement to acquire Lir Life Sciences Inc., a private biopharmaceutical company focused on developing innovative therapies for obesity and metabolic disorders. This acquisition, structured as a reverse takeover, involves the issuance of over 136 million common shares of Steep Hill, and is expected to enhance Steep Hill’s position in the biopharmaceutical sector while offering Lir access to public markets. The acquisition aims to leverage Lir’s advanced transdermal drug delivery system to potentially offer a needle-free alternative for complex biologics, aligning with the increasing demand for scalable obesity treatments.